Takedas Dengue Vaccine Recommended by World Health Organization Advisory Group for Introduction in High Dengue Burden and Transmission Areas in Children Ages Six to 16 Years : vimarsana.com

Takeda TSE4502NYSETAK today announced that the World Health Organizations WHO Strategic Advisory Group of Experts SAGE on Immunization shared recommendations for use of QDENGA Dengue Tetravalent Vaccine Live Attenuated TAK003.

Related Keywords

Japan , Panama , Brazil , Nicaragua , Osaka , Philippines , Indonesia , Dominican Republic , United States , Sri Lanka , Thailand , Argentina , Colombia , Japanese , America , Gary Dubin , Maiko Miura , World Health Organization , Data Monitoring Committee , European Union Eu Member States , Strategic Advisory Group Of Experts , Exchange Commission , Clinical Program , Public Health Burden To People Living , Takeda Pharmaceutical Company Limited , Reviewed Data , Program Across , More Than , Provide Final Guidance , Public Vaccination Programs , Growing Public Health Burden , People Living , Strategic Advisory Group , Dengue Tetravalent Vaccine , Latin America , Global Vaccine Business Unit , Dengue Efficacy Study , European Union , Member States , Product Characteristics , Annual Report , Published March , Tetravalent Dengue Vaccine Candidate , Northern European Conference , Travel Medicine , Retrieved October , Tetravalent Dengue Vaccine , Healthy Children , Retrieved July , Health Organization , Technical Report Series , What You Need , Published April , Media Contact , Takeda Pharmaceutical Company Limited Dengue Vaccine World Health Organization Advisory Group High Burden Qdenga Clinical Program Public Vaccination Programs Who Strategic Of Experts Tetravalent Gary Dubin Immunization Against Efficacy Study Virologicallyconfirmed Summary Product Characteristics ,